Pacira BioSciences, Inc.
Company Stats
- Market Cap
- $998.5M
- as of Sep 30, 2026
- Shares Outstanding
- 39.9M
- Free Float
- 69.3%
Income Statement
- Revenue
- $726.4M
- Operating Income
- $19.2M
- Net Income
- $7.0M
- EBITDA
- $110.2M
- Revenue Growth, 3Y
- 2.9%
- FCF Margin, 3Y Avg
- 21.7%
- FCF Margin, Worst Year
- 18.8%
Cash Flow
- Free Cash Flow
- $136.7M
- FCF Yield
- 13.7%
- Owner FCF Yield
- 7.9%
Balance Sheet
- Cash & Equivalents
- $158.5M
Returns & Capital
- Share Repurchases
- $148.3M
- Buyback Yield, 3Y Avg
- 5.8%
- SBC, 3Y Avg
- $52.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $726.4M | $136.7M | 18.8% |
| FY2024 | $701.0M | $178.8M | 25.5% |
| FY2023 | $675.0M | $139.5M | 20.7% |
| FY2022 | $666.8M | $115.2M | 17.3% |
| FY2021 | $541.5M | $79.9M | 14.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 28, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Coverage
November 11, 2026
Deals
Pacira Agrees to $36.50-a-Share Cash Sale to Viatris
October 11, 2026
Weekly Deals
Micro-Cap Deals Roundup for Week of Oct. 5, 2026
October 8, 2026
Deals
Viatris to Buy Pacira BioSciences in $1.65 Billion Cash Deal
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
June 30, 2026
Deals
Pacira BioSciences to Acquire iovera° in Up to $140 Million Asset-Purchase Deal
Pacira Agrees to $36.50-a-Share Cash Sale to Viatris
October 11, 2026
Weekly Deals
Micro-Cap Deals Roundup for Week of Oct. 5, 2026
October 8, 2026
Deals
Viatris to Buy Pacira BioSciences in $1.65 Billion Cash Deal
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
June 30, 2026
Deals
Pacira BioSciences to Acquire iovera° in Up to $140 Million Asset-Purchase Deal